HEXABRIX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXABRIX is an injectable contrast agent approved in 1985 by Guerbet, a small molecule used primarily in diagnostic imaging procedures. The drug facilitates radiographic visualization of internal structures and blood vessels. It is administered via injection to enhance image quality during diagnostic imaging studies.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely consolidating and shifting focus toward defending market share or transitioning to newer contrast agents.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HEXABRIX offers limited career growth due to its LOE-approaching status and lack of pipeline expansion. Roles are primarily defensive and focused on maintaining existing market position rather than driving innovation or growth.
Brand ManagerField Sales Representative
Worked on HEXABRIX at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.